metrangolo home

The 2021 Giorgio Modena medal awarded to professor Metrangolo

Professor Pierangelo Metrangolo , of the Giulio Natta Department of Chemistry, Materials and Chemical Engineering of the Politecnico di Milano has been awarded the 2021 Giorgio Modena Medal .

The award ceremony took place during the XXVII National Congress of the Italian Chemical Society. The Medal, established in 2019, is awarded every two years to honour the memory and work of Giorgio Modena, one of the masters and pioneers of research in organic physical chemistry. The Managing Board of the Division of Organic Chemistry awarded the prestigious honour to Professor Metrangolo for:

"originality and methodological rigour of his research on the chemistry of halogenated compounds. Starting from pioneering studies on weak intermolecular interactions based on halogen bonding, his research enabled molecular and supramolecular materials to be fine-tuned resulting in innovative spin-offs and applications in sectors ranging from materials science to biology ".

metrangolo

"This is a great recognition for a scientist working on intermolecular interactions," commented Professor Metrangolo. "And it is an honour that I share with my colleagues in the research group. In particular, with Giuseppe Resnati ((of whom we have spoken on MAP 9, page 40) with whom I had the good fortune to discover something new in chemistry, which will be further studied and researched for decades.”

Metrangolo refers to the halogen bond, discovered by the two scientists of the laboratories of the Department of Chemistry of the Politecnico di Milano in the late 90s, and which represented a real revolution in our understanding of intermolecular bonds. The discovery was then researched further at the Politecnico di Milano also as part of several ERC research projects funded by the European Commission (for example, we have previously mentioned Minires, a new peptide bioelastomer, characterized by exceptional elastomeric properties, in MAP issue 6, on page 31) and developed for industrial application starting in 2017 thanks to Switch2Product (in MAP issue 9, on page 32, we talked about the Innovation Challenge of Politecnico di Milano and how the "technology readiness level" of an invention is developed). .

WHAT IS HALOGEN BONDING?

In 2013, IUPAC defined "halogen bonding" as the the intermolecular interaction involving halogen atoms in a molecule as electron density acceptors. This definition highlighted the similarities of this new intermolecular interaction with commonly known hydrogen bonding, but also the more pronounced directionality of the former. Halogen bonding can now be considered for all intents and purposes as a a new tool for chemists worldwide to design and manufacture new materials and drugs (Figure 1).

metrangolo
Figure 1. X-ray structure of the kinase inhibitor, tetrabromobenzotriazole bound with its 4 bromine atoms to the target protein (taken from Current Opinion in Solid State and Materials Science 13(3-4):36-45; DOI: 10.1016/j.cossms.2009.05.001).

Metrangolo said, with a note of irony: "We didn't invent it: nature was already aware of halogen bonding. One of the most significant examples of the use of halogen bonding in nature is the thyroid hormone, thyroxine, , which has 4 iodine atoms in its chemical structure: these interact, via halogen bonding, with biomolecules in our body." The discovery of halogen bonding will help chemists and nanotechnologists design new materials based on this interaction that binds molecules together "as if they were molecular bricks," the researcher explained, "allowing the properties of the material to be modulated: for example, new drugs, from thyroid-supporting drugs to anticancer drugs that bind to the target with halogen bonding, or even for applications in cosmetics and reparative medicine" (Figure 2).

metrangolo
Figure 2. Hydrophobic pocket engineering of amyloid peptide fibrils by halogen bonding (image made by Alfonso Gautieri, Politecnico di Milano).

New therapies: a spin-off of Politecnico to treat maculopathy

La Exudative maculopathy is a very common eye desease and represents the first cause of loss of sight for people over 50To treat it, until today, it is necessary to have a frequent cycle of injection, an invasive procedure with a high impact on the life of patients, that often abandon their therapy.

To avoid the premature abandonment of the treatment, a group of researchers of the Department of Chemistry, Materials and Chemical Engineering "Giulio Natta" of Politecnico di Milano in collaboration with the Deparment of clinical and biomedical sciences "Luigi Sacco, ASST Fatebenefratelli-Sacco, Università degli Studi di Milano, it has developed Mag Shella device that with a singular injection is able to release precise doses of medicine in defined intervals.

The device was first created in 2015 from the Phd thesis of Marco Ferronibiomedical engineer of Politenico di Milano. In six years, thanks to the support of Polihub that has incubated MgShellthe spin off which has gained a lot of prizes and investments the technology and the business model were developed.

Credits: Polihub
MAG SHELL: A NEW THERAPEUTIC FRONTIER FOR EXUDATIVE MACULOPATHY

The Mag Shell ocular device is a drug "container" that is inserted, with a single injection, into the eye and releases the active ingredient gradually, thus ensuring greater patient adherence to the therapeutic protocol.

This operation is possible thanks to the conformation of the device itself, which alternates layers of biodegradable materials, consisting of magnesium or its alloys, with drug doses.

materiali biodegradabili, costituiti da magnesio o da sue leghe, a dosi di farmaco.

"Today this means avoiding that 40% of patients who drop out of therapy go blind, it means drastically reducing the social impact that chronic diseases have" explains Ferroni in an interview.

The advantages of this procedure are many: in addition to the reduction of costs and the impact of current drug treatment on maculopathic patients, hospital staff and on healthcare costs, there are promising possibilities for using MagShell in other areas of pharmaceutical application as well.

The device is currently in a preclinical in vitro trial phase and the first animal pilot study will begin soon.

primo studio pilota su animale.

Cover Photo: Polihub

MAP is the magazine of the Alumni of Politecnico di Milano The magazine is your compass to navigate everything that is developing and changing in our University. Below you will find a related article : if you like what you are seeing, support us . You will be able to collect your copy for free.